

**FIRST FRENCH-ISRAELI INTERNATIONAL CONFERENCE ON B CELLS AND THERAPEUTIC
ANTIBODIES**

JERUSALEM, ISRAEL

**B cell development, antibody diversity and function:
From basic science to therapeutic antibodies**

October 23 – 25, 2011, Jerusalem, Israel

**With the official support of the Hebrew University of Jerusalem, the Hadassah Medical School, the
Paris Descartes University and the French Embassy - Institut Français in Israel**

.....
Organizers

Reuven Laskov (Israel)
Claude-Agnès Reynaud (France)
Jean-Luc Teillaud (France)

Advisory Board and Scientific Committee

Dan Eilat (Israel)
Cécile Goujet-Zalc (France)
David Naor (Israel)
Haim Tapiero (France)
Yaakov Naparstek (Israel)

With the sponsorship of: the Israeli Immunological Society (IIS), the French Society of Immunology (SFI), the AVIESAN-ITMO Technologies pour la Santé, the AVIESAN-ITMO Immunologie, Hématologie, Pneumologie, the European Federation of Immunological Societies (EFIS), the European Friends of the Hebrew University of Jerusalem – La Maison de France, the Canadian Friends of the Hebrew University of Jerusalem, and of the following companies: CureTech Ltd, Transgene, Laboratoire français du Fractionnement et des Biotechnologies (LFB), Laboratoires Pierre Fabre, Sanofi (provisional list)

SCIENTIFIC PROGRAM

SUNDAY OCTOBER 23, 2011

8:00 - 9:00 **Registration**

9:00 – 9:30 **Opening Remarks: (subjected to their agreements)**

The City Mayor of Jerusalem or his representative
Prof. Eric Seboun, Attaché for Science, Embassy of France
President of the Hebrew University or his representative

Chairperson: Claude-Agnès Reynaud/Jean-Luc Teillaud

9:30 – 10:15 **Special Guest Lecture - *Michael Neuberger*** (Laboratory of Molecular Biology, Medical Research Council, Cambridge, United Kingdom)
The making of high affinity antibodies: in vivo and in vitro approaches

10:15- 10:45 ***Michael Steinitz*** (Hebrew University-Medical School, Jerusalem, Israel)
Thirty years of human monoclonal antibodies: Past present and future developments

10:45- 11:00 **Coffee break**

SESSION 1: The life of a B cell: diversity, memory, aging and death

Chairpersons: Michael Schlesinger /Michel Cogné

11:00- 11:30 ***Claude-Agnès Reynaud*** (Faculté de Médecine, INSERM U. 783, Université Paris Descartes, Paris, France)
Diversity of B cell memory subsets

11:30 - 12:00 ***Idit Shachar*** (Weizmann Institute of Science, Israel)
Molecular mechanisms of B cell survival in health and disease

12:00 - 12:30 ***Doron Melamed*** (Technion, Medical School, Haifa, Israel)
B cell development in aging

12:30 - 12:55 ***Esther Breij*** (AIMM Therapeutics B.V., Amsterdam, The Netherlands)
Generation of stable antibody-producing human memory B cells by genetic programming

12:55 - 13:20 ***Majid Mehtali*** (Vivalis, Saint-Herblain, France)
The use of human B lymphocytes for the manufacturing of fully human monoclonal antibodies

13:20 - 14:15 **LUNCH (& Posters)**

SESSION 2: Molecular events: the making of an antibody molecule

Chairpersons: Claude-Agnès Reynaud/Ramit Mehr

14:15 – 14:45 ***Bertrand Nadel*** (Centre d'Immunologie de Marseille-Luminy (CIML), INSERM U631, CNRS UMR6102, Université de la Méditerranée, Marseille, France)
Follicular lymphomagenesis: towards closing the gap between early precursors and early stages

14:45 - 15:15 ***Reuven Laskov*** (Hebrew University - Medical school, Jerusalem, Israel)
Ongoing somatic hypermutation in the IgVH alleles of EBV transformed rheumatoid factor-producing lymphoblastoid cell line

15:15 - 15:45 ***Dan Eilat*** (Hadassah Hospital, Jerusalem, Israel)
B cell receptor editing in autoimmunity

15:45 - 16:15 *Bernardo Reina-San-Martin* (Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM U. 964-CNRS UMR 7104, Université de Strasbourg, Illkirch, France)
Molecular mechanisms driving immunoglobulin Class Switch Recombination

16:15 - 16:30 **Coffee Break / Posters**

Chairpersons: **Jossi Haimovich/Bertrand Nadel**

16:30 - 17:00 *Michel Cogné* (UMR CNRS 6101, Centre National de la Recherche Scientifique, Université de Limoges, France)
Regulation of immunoglobulin expression in mature B cells

17:00 - 17:30 *Yehudit Bergman* (Hebrew University-Medical school, Jerusalem, Israel)
Epigenetic control of Ig allelic exclusion

17:30 - 18:00 *Renato Monteiro* (INSERM U. 699, Paris, France)
Control of Inflammation through IgA and IgA Fc Receptors: a Therapeutic Perspective

18:00 - 18:30 *Sven Berger* (Institut de Recherche Pierre Fabre, Saint Julien-en-Genevois, France)
Engineering the antibody hinge and Fc regions to modulate effector functions: from discovery to clinical applications

18:30 - 20:00 **Posters**

MONDAY OCTOBER 24, 2011

SESSION 3: Antibody effector functions: molecules and cells in a complex environment

Chairpersons: **Josée Golay/Isaac Witz**

9:00 - 9:30 *Wolf-Herman Fridman* (Centre de Recherche des Cordeliers, INSERM U. 872, Université Paris Descartes, Paris, France)
Shaping an efficient immune reaction in the tumor micro-environment

9:30 - 10:00 *Yoram Reiter* (Technion, Haifa, Israel)
Engineering the immune system effector cells and molecules for novel anti-tumor therapeutics

10:00 - 10:30 *David Naor* (Hebrew University-Medical school, Jerusalem, Israel)
Anti-CD44 and the hyaluronic acid mediated motility receptor (CD168) in cancer and autoimmunity

10:30 - 11:00 *Rinat Rotem-Yehudar* (CureTech, Yavne)
CT-011, anti PD-1 antibody for the treatment and control of hematological malignancies and solid tumors

11:00 - 11:15 **Coffee break**

Chairpersons: **Wolf-Herman Fridman/Boaz Tirosh**

11:15 - 11:45 *Hélène Haegel* (Transgene, Illkirch Graffenstaden, France)
Monoclonal antibodies with multi-intervention points: Transgene's Mab to CD115 case study

11:45 - 12:15 *Zelig Eshhar* (Weizmann Institute of Science, Rehovot, Israel)
Redirection of T-cells with antibody-based specificity

12:15 - 12:45 *C. de Romeuf* (Laboratoire français du Fractionnement et des Biotechnologies (LFB), Les Ulis, France)
Monoclonal antibodies with improved interaction with FcγRIIIa (CD16) mediate high cytotoxicity and fast *in vivo* clearance

12:45 -13:15 *Itai Benhar* (Tel Aviv University, Tel Aviv, Israel)
Inclonals: IgG and IgG based fusion proteins

13:15 -14:15 **LUNCH (& Posters)**

Free Afternoon: Visit of the Old City

TUESDAY OCTOBER 25, 2011

Session 4: Engineering antibodies

Chairpersons: Eitan Yefenof

9:00 - 9:30 *Irit Sagi* (Weizmann Institute, Rehovot)
Metallobodies- anti-metalloprotease inhibitory antibodies exhibiting potential use in therapy of invasive diseases

9:30 – 10:00 *Serge Muyldermans* (Laboratory of Cellular and Molecular Immunology, VIB, Department of Molecular and Cellular Interactions, Vrije Universiteit Brussel, Brussel, Belgium)
Camelidæ immunoglobulins: from structural lessons to development of a nanobody technology with versatile applications

10:00 - 10:30 *Roger MacKenzie* (Institute for Biological Sciences, National Research Council of Canada, Ottawa, Canada)
Formatting single-domain antibodies for tumor targeting

10:30 - 11:00 *Yafit Stark* (TEVA Pharmaceutical Industries, Netanya, Israel)
Challenges in the Clinical Development of Biosimilars

11:00 - 11:15 **Coffee Break**

Session 5: Learning from treatment with therapeutic antibodies

Chairpersons: Marie-Caroline Dieu-Nosjean /Dror Mevorach

11:15 - 11:45 *Josée Golay* (Laboratory of Cellular and Gene Therapy "G. Lanzani," Ospedali Riuniti di Bergamo, Bergamo, Italy)
Macrophages in the therapeutic activity of rituximab: a central player within the immune network

11:45 – 12:15 *Jean-Luc Teillaud* (Centre de Recherche des Cordeliers, INSERM U.872, Université Paris Descartes, Paris, France)
Induction of adaptive cellular immune response by anti-CD20 antibody treatment

12:15 – 12:45 *Nurit Hollander* (TAU, Tel Aviv)
Combination of anti-CD20 antibody treatment and vaccination in the therapy of B-cell lymphoma

12:45 – 14:00 **LUNCH**

Session 6: Monoclonal antibodies in the treatment of auto-immune and viral diseases

Chairpersons: Yehuda Shoenfeld/Renato Monteiro

14:00 – 14:30 *Luc Mouthon* (Hôpital Cochin, Université Paris Descartes, Paris, France)
Clinical use of therapeutic antibodies in inflammatory and auto-immune diseases

14:30 – 15:00 *Yaakov Naparstek* (Hadassah Hospital, Jerusalem, Israel)
Anti-HSP protective antibodies - a new therapeutic approach for RA and IBD

15:00 – 15:30 *Yves Poulin* (Hôpital Hôtel-Dieu de Québec, Université Laval, Québec, Qc, Canada)
Biologics that change the life of psoriasis sufferers

15:30 – 15:45

Coffee Break

15:45 – 16:15 *Roberto Burioni* (Laboratorio di Microbiologia e Virologia, Università Vita-Salute San Raffaele, Milan, Italy)
Human monoclonal antibodies as potential anti-HCV and anti-influenza drugs

16:15 – 16:45 *Jamie Scott* (Department of Molecular Biology and Biochemistry and Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada)
Features of antibodies produced during infection by HIV-1 and other chronic viruses, and their implications for vaccine design

Chairperson: Reuven Laskov

16:45 – 17:30 **Special Guest Lecture** - *Matthew Scharff* (Department of Cell Biology, Albert Einstein College of Medicine of Yeshiva University, New York, USA)
The targeting of AID and error prone repair to Ig regions

17:30-17:45 **Concluding Remarks:** Reuven Laskov, Claude-Agnès Reynaud, Jean-Luc Teillaud

20:00

GALA DINER